Enteral stenting for gastric outlet obstruction and afferent limb syndrome following pancreaticoduodenectomy. by Kwong, Wilson T et al.
UC San Diego
UC San Diego Previously Published Works
Title
Enteral stenting for gastric outlet obstruction and afferent limb syndrome following 
pancreaticoduodenectomy.
Permalink
https://escholarship.org/uc/item/14t3q29p
Journal
Annals of gastroenterology, 27(4)
ISSN
1108-7471
Authors
Kwong, Wilson T
Fehmi, Syed M
Lowy, Andrew M
et al.
Publication Date
2014
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
© 2014 Hellenic Society of Gastroenterology www.annalsgastro.gr
Annals of Gastroenterology (2014) 27, 413-417C A S E  S E R I E S
Enteral stenting for gastric outlet obstruction and aff erent limb 
syndrome following pancreaticoduodenectomy
Wilson T. Kwonga, Syed M. Fehmia, Andrew M. Lowyb, Thomas J. Savidesa
University of California, San Diego Health Sciences, La Jolla, CA, USA
Abstract Background Obstruction of the aff erent or eff erent limbs of a gastrojejunal anastomosis is a 
potential complication aft er pancreaticoduodenectomy (PD) resulting in either gastric outlet 
obstruction or aff erent limb syndrome. Th e use of self-expanding metal stents for the management 
of anastomotic strictures aft er resection of pancreatic cancer has not been well studied. We present 
four such cases and review published data regarding this population.
Methods Retrospective chart review and literature search. Outcomes were summarized with 
descriptive statistics.
Results At our institution, 4  patients underwent metal stent placement for gastrojejunal 
obstruction aft er PD for pancreatic cancer. Enteral stents were placed in two patients across the 
aff erent limb, in one patient across the eff erent limb, and in another patient across both limbs. 
Similar cases in the literature revealed that the anastomotic stricture was malignant in 26 of 
27 cases. Clinical improvement occurred in 88%. Aff erent limb syndrome was successfully treated 
in 5 of 6 cases. Median survival was 3.5 months aft er stent placement.
Conclusions Eff ective palliation of both gastric outlet obstruction and aff erent limb syndrome 
aft er PD can be provided with enteral stenting. Gastrojejunal strictures aft er PD for pancreatic 
cancer are usually malignant with median survival of 3.5 months aft er stent placement.
Keywords Stent, pancreaticoduodenectomy, gastric outlet obstruction, aff erent limb syndrome, 
pancreatic cancer
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Introduction
Obstruction of the aff erent or eff erent limbs of the 
gastrojejunal anastomosis is a recognized complication of 
pancreaticoduodenectomy (PD). Anastomotic obstruction 
results in either gastric outlet obstruction or aff erent limb 
syndrome. Immediate postoperative obstruction is usually 
related to a technical error or edema, while late obstruction 
may be the result of malignancy, adhesions, radiation induced 
strictures, or internal hernias. Traditionally, obstruction 
has been managed surgically or with balloon dilation [1,2]. 
However, the development of self-expanding metal stents 
(SEMS) has provided a less invasive alternative. While studies 
have shown SEMS to be an eff ective treatment option in 
malignant gastric outlet obstruction [3], the use of SEMS for 
anastomotic strictures aft er resection of pancreatic cancer has 
not been studied.
Methods
We report a case series of four patients who underwent 
enteral stenting of the aff erent or eff erent limb aft er PD for 
pancreatic cancer. Th e patients were identifi ed through an 
endoscopy database and retrospective chart review. Th is study 
was approved by our institutional review board.
Similar reported cases of aff erent or eff erent limb stenting 
aft er PD for pancreatic cancer were identifi ed through PubMed 
search using the terms: enteral stent, PD, pancreatic cancer, 
and gastric outlet obstruction. Th e results were summarized 
using descriptive statistics.
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Case series
Case 1
A 75-year-old man underwent PD for T3N1 pancreatic 
adenocarcinoma with negative margins. He developed recurrent 
disease and eleven months following resection, he developed 
inability to tolerate solid foods. Computed tomography (CT) 
scan revealed a dilated stomach consistent with gastric outlet 
obstruction. Upper endoscopy demonstrated a tight angulation 
at the eff erent limb anastomosis (Fig. 1). An uncovered metal 
stent (27  mm  ×  60  mm, Evolution Duodenal Stent, Cook 
Medical, Bloomington, IN) was placed in the eff erent limb 
and the patient was subsequently able to resume a regular 
diet. Positron emission tomography CT scan demonstrated 
malignant recurrence surrounding the stent (Fig. 2). Five weeks 
later, he developed recurrent vomiting. Repeat endoscopy 
revealed stent occlusion from tissue ingrowth and food debris. 
A  second uncovered metal stent (22  mm ×  90  mm, Boston 
Scientifi c WallFlex Duodenal Stent, Natick, MA) was placed 
within the existing stent with resolution of his symptoms. 
Four weeks later, the patient developed elevated total bilirubin 
5.9  mg/dL, and alkaline phosphatase 488 U/L. An upper GI 
series demonstrated a patent eff erent limb without opacifi cation 
of the aff erent limb, consistent with aff erent limb syndrome. 
Esophagogastroduodenoscopy (EGD) revealed a strictured 
aff erent limb and an uncovered metal stent (22 mm × 90 mm, 
Evolution Duodenal Stent, Cook Medical, Bloomington, IN) 
was placed (Fig.  3). Th e patient’s bilirubin normalized aft er 
stent placement. Six weeks later, he developed bilious emesis. 
Endoscopic and fl uoroscopic evaluation revealed a narrowing 
of the distal eff erent limb stent followed by a 2  cm stricture 
immediately beyond the stent. A  longer 22  mm × 120  mm 
stent (Evolution Duodenal Stent, Cook Medical, Bloomington, 
IN) was placed through the existing stents (Fig.  4). Despite 
chemotherapy, the patient developed omental metastases and 
an enlarging porta hepatis mass. Th e patient passed away 
3 weeks aft er stent placement.
Case 2
A 58-year-old woman underwent PD for T3N0 pancreatic 
adenocarcinoma with negative margins. She developed 
recurrent disease and 21 months postoperatively she developed 
abdominal pain, and fevers. Her labs revealed an elevated 
WBC count of 12,000, total bilirubin 3.0 mg/dL, and alkaline 
phosphatase 658 U/L. CT scan demonstrated dilation of 
proximal small bowel concerning aff erent limb obstruction, 
and blood cultures grew Escherichia coli. EGD revealed a 
strictured aff erent limb and a 22 mm × 90 mm metal duodenal 
stent (Boston Scientifi c WallFlex Duodenal Stent, Natick, MA) 
was placed across the stricture with immediate fl ow of bilious 
fl uid. Th e patient improved clinically and her bilirubinemia 
resolved. Ultimately, she developed progressive disease and 
died 6 months following stent placement.
Figure 1 Tight angulation of the eff erent limb of a gastrojejunal 
anastomosis. A catheter is successfully passed across the angulation
Figure 2 Positron emission tomography computed tomography scan 
demonstrating malignant recurrence surrounding an eff erent limb stent
Figure 3 Fluoroscopy image demonstrating placement of an aff erent 
limb stent alongside an eff erent limb stent in a patient with both 
aff erent and eff erent limb obstruction
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Case 3
A 68-year-old woman with T3N1 pancreatic 
adenocarcinoma presented with progressive vomiting 
10 months after PD with positive margins. An upper GI series 
showed a tight angulation at the efferent limb with minimal 
passage of contrast. Upper endoscopy was performed and 
1000  mL of bilious fluid was aspirated from her stomach. 
The efferent limb was narrowed and a 22  mm × 90  mm 
metal stent (Boston Scientific WallFlex, Natick, MA) was 
deployed successfully. Shortly after deployment, the stent 
migrated into the stomach likely secondary to the acute 
angulation of the efferent limb. Repeat endoscopy was 
performed and a 22  mm × 90  mm uncovered metal stent 
with dual flares (Evolution Duodenal Stent, Cook Medical, 
Bloomington, IN) was placed with two hemoclips anchoring 
the intragastric portion of the stent to prevent migration. 
The stent remained in good position and the patient 
experienced symptomatic improvement. She subsequently 
demonstrated progressive disease with malignant ascites 
and expired 3 weeks later.
Case 4
A 47-year-old man underwent PD with negative margins 
for T3N1 pancreatic adenocarcinoma. Shortly thereaft er, he 
developed vomiting and upper GI series demonstrated delayed 
opacifi cation of the eff erent limb. Upper endoscopy revealed 
400  mL of bilious fl uid in the stomach and an anastomotic 
stricture of the eff erent limb which extended 40 mm. A 22 mm 
x 60  mm uncovered metal stent (Evolution Duodenal Stent, 
Cook Medical, Bloomington, IN) was successfully placed 
allowing him to tolerate a regular diet. He later developed 
progressive ascites, peritoneal carcinomatosis with biliary 
dilation and died three months aft er stent placement.
Results
A literature search for cases of aff erent or eff erent limb 
obstruction aft er pancreatic surgery for pancreatic cancer 
treated with enteral stent identifi ed an additional 24  cases 
to our 4  cases. 16  patients underwent PD and 12  patients 
underwent palliative gastrojejunostomy. 24  patients received 
eff erent limb stents and 8 patients received aff erent limb stents 
(one patient received 2 stents and another from this case series 
received 4 stents). Th e etiology of obstruction was malignant 
in 26 of 27 patients. Stent placement was successful in 100% 
of cases and the rate of clinical improvement was 88% (22 of 
25  patients). A  variety of stents were utilized (Table  1) with 
the Wallstent (Boston Scientifi c, Natick, Massachusetts) as 
the most commonly utilized stent (8  patients). Th e median 
survival aft er enteral stent placement was 3.5 months.
Discussion
Late obstruction of the aff erent or eff erent limbs aft er PD 
for pancreatic cancer is oft en secondary to disease recurrence. 
Such obstruction impairs quality of life and generally represents 
a pre-terminal event. Less commonly, adhesions and radiation 
enteropathy may contribute. Palliative gastrojejunostomy in 
patients with pancreatic cancer is associated with a high 30-
day mortality [4] and reoperation for anastomotic strictures 
likely carries a similarly high complication rate. A less invasive 
endoscopic approach is therefore attractive in a patient 
population with limited survival.
Review of published cases in the literature reveals that the 
etiology of anastomotic obstruction was malignant in 26 of 
27  cases (Table  1). Among our cases, malignant recurrence 
was not evident endoscopically. Instead, acute angulation 
at the stricture was the most common fi nding, seen in half 
of our cases. Despite the absence of endoscopic evidence of 
malignancy, all of our patients demonstrated evidence of 
disease recurrence on imaging either at the time of endoscopy 
or shortly aft er and none survived more than 6 months aft er 
stent placement. Th e median survival among pancreatic cancer 
patients with anastomotic strictures was 3.5 months.
Stenting of anastomotic strictures aft er PD or palliative 
gastrojejunostomy for pancreatic cancer was technically 
successful in all cases. Clinical improvement was observed in 
88% of patients (22 of 25 cases), which is consistent with rates of 
improvement seen in other case series of stenting for malignant 
gastric outlet obstruction [5]. Obstruction of the eff erent limb 
was more common than aff erent limb obstruction (24 eff erent 
versus 8 aff erent limb stents). Enteral stent management of 
aff erent loop syndrome was successful in 5 of 6 cases. Th e single 
unsuccessful case was performed during early years of enteral 
stenting where the stent utilized was smaller in diameter than 
most enteral stents currently in use [6].
It is technically feasible to concurrently place enteral stents 
in both the aff erent and eff erent limbs without compromising 
the patency of either stent. We report the second case of 
Figure 4 A metal stent in the aff erent limb and three metal stents in the 
eff erent limb in a patient with aff erent loop syndrome and recurrent 
malignant obstruction of the eff erent limb
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concurrent aff erent and eff erent stents aft er pancreatic cancer 
surgery [7]. Our patient required three eff erent limb stents for 
recurrent malignant obstruction along with an aff erent limb 
stent. Th is case also demonstrates that recurrent obstruction 
can be managed with progressively longer stents.
Few complications were reported in the literature. Th e 
main complication is stent migration. We reported one 
patient with proximal migration of the stent into the stomach. 
A subsequent attempt utilized two hemoclips to anchor a dual 
fl anged stent. Th ere was one reported case of stent migration 
into the terminal ileum in the only patient with a benign 
stricture [8]. Th ere were no cases of perforation, bleeding, 
or death. Potential complications of enteral stent placement 
include bleeding, tumor ingrowth/overgrowth, fi stulas, and 
obstruction [9]. Th ese complications can usually be managed 
endoscopically, oft en with placement of a second stent. We 
recommend uncovered, dual fl anged stents to minimize risk 
of stent migration. Shorter stents (40 or 60 mm) are preferable 
if the stricture is not long so as to reduce trauma to the 
contralateral wall.
In conclusion, the development of an anastomotic stricture 
aft er PD for pancreatic cancer is usually malignant and carries 
a poor prognosis. Palliation of both gastric outlet obstruction 
and aff erent limb syndrome can be provided with endoscopic 
placement of enteral stents.
References
1. Oida T, Mimatsu K, Kano H, et al. Palliative enteric 
bypass for malignant gastric outfl ow obstruction aft er 
pancreaticoduodenectomy in early recurrent pancreatic cancer. 
Hepatogastroenterology 2011;58:1360-1367.
2. Pannala R, Brandabur JJ, Gan SI, et al. Aff erent limb syndrome 
and delayed GI problems aft er pancreaticoduodenectomy for 
pancreatic cancer: single-center, 14-year experience. Gastrointest 
Endosc 2011;74:295-302.
3. Brimhall B, Adler DG. Enteral stents for malignant gastric outlet 
obstruction. Gastrointest Endosc Clin N Am 2011;21:389-403.
4. Weaver DW, Wiencek RG, Bouwman DL, et al. Gastrojejunostomy: 
Is it helpful for patients with pancreatic cancer? Surgery 
1987;102:608-613.
5. Masci E, Viale E, Mangiavillano B, et al. Enteral self-expandable 
metal stent for malignant luminal obstruction of the upper and 
lower gastrointestinal tract: a prospective multicentric study. J Clin 
Gastroenterol 2008;42:389-394.
Table 1 Summary of published cases of anastomotic strictures managed with stents aft er pancreaticoduodenectomy or gastrojejunostomy for 
pancreatic cancer
Author year # Age sex Surg Stent location Stricture Stent Improve Survival
Kozarek [6], 1992 1 NA PD Aff erent Cancer Z stent No 3 mo
Binkert [10], 1996 1 30M GJ Eff erent Cancer Wallstent Yes 5 mo
Nevitt [11], 1998 1 77F GJ Eff erent Cancer Z stent No 5 mo
Soetikno [12], 1998 1 57M GJ Eff erent Cancer Wallstent Yes 2 mo
Adler [7], 2002 1 NA GJ Aff erent
Eff erent
Cancer Wallstent N/A N/A
Ely [13], 2003 1 NA PD Eff erent Cancer Wallstent Yes 2 mo
Fiocca [14], 2006 4 NA GJ Eff erent Cancer Wallstent Yes N/A
Maetani [15], 2006 2 NA PD Eff erent Cancer Niti-S N/A N/A
Stawowy [16], 2007 1 54 GJ Eff erent Cancer N/A Yes 2 mo
Lopes [17], 2008 2 NA GJ Eff erent Cancer N/A N/A N/A
Gutzeit [18], 2009 1 30M PD Eff erent Cancer Wallstent Yes 5 mo
Akaraviputh [19], 2010 1 60M PD Aff erent Cancer Wallstent Yes >6 mo
Kim [20], 2011 2 52F
62F
PD
PD
Aff erent
Aff erent
Cancer
Cancer
Hanaro
Niti-S
Yes
Yes
N/A
N/A
Pannala [2], 2011 4 NA PD 1Aff erent
3Eff erent
Cancer Wallstent Yes N/A
Tol [8], 2012 1 NA PD Eff erent Adhesion Hanaro Yes >10 mo
Current Series 4 68F
47M
58F
75M
PD
PD
PD
PD
Eff erent
Eff erent
Eff erent
Aff /Eff ×3
Cancer
Cancer
Cancer
Cancer
Evolution
Evoluion
Wallfl ex
Evolution
Yes
Yes
Yes
Yes
3 wk
3 mo
6 mo
5 mo
Totals 28 55.8
yrs
16 PD
12 GJ
8 Aff 
24 Eff 
26/27
Cancer
22/25
Yes
3.5 mo
median
#, number of patients; GJ, gastrojejunostomy; PD, pancreaticoduodenectomy; yrs, years; mo, months; wk, weeks
Survival is after stent placement; Z stent - Wilson Cook, Wallstent - Boston Scientific, Hanaro stent - M.I. Tech, Evolution - Cook Medical, Niti-S - Taewoong Medical
Enteral stents aft er pancreaticoduodenectomy  417
Annals of Gastroenterology 27
6. Kozarek RA, Ball TJ, Patterson DJ. Metallic self-expanding 
stent application in the upper gastrointestinal tract: caveats and 
concerns. Gastrointest Endosc 1992;38:1-6.
7. Adler DG, Baron TH. Endoscopic palliation of malignant gastric 
outlet obstruction using self-expanding metal stents: experience in 
36 patients. Am J Gastroenterol 2002;97:72-78.
8. Tol JA, Jansen JM, Donkervoort SC. Anastomotic stenosis aft er 
pancreaticoduodenectomy: an endoscopic solution. Gastrointest 
Endosc 2012;76:1067-1068.
9. Gaidos JK, Draganov PV. Treatment of malignant gastric outlet 
obstruction with endoscopically placed self-expandable metal 
stents. World J Gastroenterol 2009;15:4365-4371.
10. Binkert CA, Jost R, Steiner A, et al. Benign and malignant stenoses 
of the stomach and duodenum: treatment with self-expanding 
metallic endoprostheses. Radiology 1996;199:335-338.
11. Nevitt AW, Vida F, Kozarek RA, et al. Expandable metallic 
prostheses for malignant obstructions of gastric outlet and 
proximal small bowel. Gastrointest Endosc 1998;47:271-276.
12. Soetikno RM, Lichtenstein DR, Vandervoort J, et al. Palliation 
of malignant gastric outlet obstruction using an endoscopically 
placed Wallstent. Gastrointest Endosc 1998;47:267-270.
13. Ely CA, Arregui ME. Th e use of enteral stents in colonic and gastric 
outlet obstruction. Surg Endosc 2003;17:89-94.
14. Fiocca E, Ceci V, Donatelli G, et al. Palliative treatment of upper 
gastrointestinal obstruction using self-expansible metal stents. Eur 
Rev Med Pharmacol Sci 2006;10:179-182.
15. Maetani I, Isayama H, Mizumoto Y. Palliation in patients with 
malignant gastric outlet obstruction with a newly designed enteral 
stent: a multicenter study. Gastrointest Endosc 2007;66:355-360.
16. Stawowy M, Kruse A, Mortensen FV, et al. Endoscopic stenting 
for malignant gastric outlet obstruction. Surg Laparosc Endosc 
Percutan Tech 2007;17:5-9.
17. Lopes CV, Pesenti C, Bories E, et al. Self-expandable metallic stents 
for palliative treatment of digestive cancer. J  Clin Gastroenterol 
2008;42:991-996.
18. Gutzeit A, Binkert CA, Schoch E, et al. Malignant gastroduodenal 
obstruction: treatment with self-expanding uncovered wallstent. 
Cardiovasc Intervent Radiol 2009;32:97-105.
19. Akaraviputh T, Trakarnsanga A, Tolan K. Endoscopic treatment 
of acute ascending cholangitis in a patient with Roux-en-Y 
limb obstruction aft er a Whipple operation. Endoscopy 2010;42 
(Suppl 2):E335-E336.
20. Kim JK, Park CH, Huh JH, et al. Endoscopic management of aff erent 
loop syndrome aft er a pylorus preserving pancreatoduodenectomy 
presenting with obstructive jaundice and ascending cholangitis. 
Clin Endosc 2011;44:59-64. 
